Author: Karolina Kujawa
Publisher: Datamonitor Healthcare
MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs. Based on Mitsubishi Tanabe Pharma’s plan to complete the Phase III study in the elderly in 2019, the company intends to launch the vaccine in the US and EU for adults aged 18–64 years in time for the 2020/21 season (Mitsubishi Tanabe Pharma, 2018), and Datamonitor Healthcare expects launch for the elderly in the 2021/22 season. The company anticipated starting Phase III trials in the pediatric population by the end of 2018, but as no trials have been initiated so far, Datamonitor Healthcare expects the trials will not begin until H1 2019. Provided positive results are obtained in the pediatric population, the company could launch the vaccine as early as the 2022/23 season.
MT-2271 is a plant-based, recombinant virus-like particle (VLP) QIV seasonal influenza vaccine in development by Mitsubishi Tanabe Pharma. It contains a mix of recombinant hemagglutinin proteins expressed as VLPs.
4 Drug Overview
5 Product Profiles
5 MT-2271 : Seasonal influenza vaccines
LIST OF TABLES
6 Table 1: MT-2271 drug profile
7 Table 2: Clinical trials of MT-2271 for seasonal influenza vaccination
8 Table 3: MT-2271 for seasonal influenza – SWOT analysis
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.